The Division of AIDS (DAIDS) maintains contracts that can potentially provide limited pre-clinical services including manufacturing, analytical chemistry, preclinical pharmacology and toxicology resources to investigators who are working on the development of therapeutics targeting HIV/AIDS and AIDS-related opportunistic infections, including TB.
Main Areas of Focus
- The focus of the program is to facilitate the advancement of promising drug candidates from bench to clinic.
- DAIDS is especially interested in the development of long acting formulations of antiretroviral drugs, as well as antiretroviral drugs targeting novel viral, and possibly host, proteins.
Joe Fitzgibbon, Drug Development and Clinical Sciences Branch